These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 36414182)

  • 1. Selective activation of striatal indirect pathway suppresses levodopa induced-dyskinesias.
    Castela I; Casado-Polanco R; Rubio YV; da Silva JA; Marquez R; Pro B; Moratalla R; Redgrave P; Costa RM; Obeso J; Hernandez LF
    Neurobiol Dis; 2023 Jan; 176():105930. PubMed ID: 36414182
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Striatal activation by optogenetics induces dyskinesias in the 6-hydroxydopamine rat model of Parkinson disease.
    F Hernández L; Castela I; Ruiz-DeDiego I; Obeso JA; Moratalla R
    Mov Disord; 2017 Apr; 32(4):530-537. PubMed ID: 28256089
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Striatal D1 medium spiny neuron activation induces dyskinesias in parkinsonian mice.
    Perez XA; Zhang D; Bordia T; Quik M
    Mov Disord; 2017 Apr; 32(4):538-548. PubMed ID: 28256010
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Eltoprazine prevents levodopa-induced dyskinesias by reducing striatal glutamate and direct pathway activity.
    Paolone G; Brugnoli A; Arcuri L; Mercatelli D; Morari M
    Mov Disord; 2015 Nov; 30(13):1728-38. PubMed ID: 26207892
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting β-arrestin2 in the treatment of L-DOPA-induced dyskinesia in Parkinson's disease.
    Urs NM; Bido S; Peterson SM; Daigle TL; Bass CE; Gainetdinov RR; Bezard E; Caron MG
    Proc Natl Acad Sci U S A; 2015 May; 112(19):E2517-26. PubMed ID: 25918399
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optogenetic activation of striatal cholinergic interneurons regulates L-dopa-induced dyskinesias.
    Bordia T; Perez XA; Heiss J; Zhang D; Quik M
    Neurobiol Dis; 2016 Jul; 91():47-58. PubMed ID: 26921469
    [TBL] [Abstract][Full Text] [Related]  

  • 7. L-DOPA treatment selectively restores spine density in dopamine receptor D2-expressing projection neurons in dyskinetic mice.
    Suárez LM; Solís O; Caramés JM; Taravini IR; Solís JM; Murer MG; Moratalla R
    Biol Psychiatry; 2014 May; 75(9):711-22. PubMed ID: 23769604
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Shedding light on dyskinesias.
    Castela I; Hernandez LF
    Eur J Neurosci; 2021 Apr; 53(7):2398-2413. PubMed ID: 32394612
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Multimodal Serotonergic Agent Vilazodone Inhibits L-DOPA-Induced Gene Regulation in Striatal Projection Neurons and Associated Dyskinesia in an Animal Model of Parkinson's Disease.
    Altwal F; Moon C; West AR; Steiner H
    Cells; 2020 Oct; 9(10):. PubMed ID: 33050305
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Striatal tyrosine hydroxylase-positive neurons are associated with L-DOPA-induced dyskinesia in hemiparkinsonian mice.
    Keber U; Klietz M; Carlsson T; Oertel WH; Weihe E; Schäfer MK; Höglinger GU; Depboylu C
    Neuroscience; 2015 Jul; 298():302-17. PubMed ID: 25892702
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Loss of glutamic acid decarboxylase (Gad67) in striatal neurons expressing the Drdr1a dopamine receptor prevents L-DOPA-induced dyskinesia in 6-hydroxydopamine-lesioned mice.
    Zhang K; Chammas C; Soghomonian JJ
    Neuroscience; 2015 Sep; 303():586-94. PubMed ID: 26188284
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pregnenolone for the treatment of L-DOPA-induced dyskinesia in Parkinson's disease.
    Corsi S; Scheggi S; Pardu A; Braccagni G; Caruso D; Cioffi L; Diviccaro S; Gentile M; Fanni S; Stancampiano R; Gambarana C; Melcangi RC; Frau R; Carta M
    Exp Neurol; 2023 May; 363():114370. PubMed ID: 36878398
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A2A receptor antagonists do not induce dyskinesias in drug-naive or L-dopa sensitized rats.
    Jones N; Bleickardt C; Mullins D; Parker E; Hodgson R
    Brain Res Bull; 2013 Sep; 98():163-9. PubMed ID: 23838432
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The nicotine-mediated decline in l-dopa-induced dyskinesias is associated with a decrease in striatal dopamine release.
    Bordia T; McIntosh JM; Quik M
    J Neurochem; 2013 Apr; 125(2):291-302. PubMed ID: 23373725
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selective loss of bi-directional synaptic plasticity in the direct and indirect striatal output pathways accompanies generation of parkinsonism and l-DOPA induced dyskinesia in mouse models.
    Thiele SL; Chen B; Lo C; Gertler TS; Warre R; Surmeier JD; Brotchie JM; Nash JE
    Neurobiol Dis; 2014 Nov; 71():334-44. PubMed ID: 25171793
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cholinergic control of striatal neurons to modulate L-dopa-induced dyskinesias.
    Bordia T; Perez XA
    Eur J Neurosci; 2019 Mar; 49(6):859-868. PubMed ID: 29923650
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic deletion of GPR88 enhances the locomotor response to L-DOPA in experimental parkinsonism while counteracting the induction of dyskinesia.
    Mantas I; Yang Y; Mannoury-la-Cour C; Millan MJ; Zhang X; Svenningsson P
    Neuropharmacology; 2020 Jan; 162():107829. PubMed ID: 31666199
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Implanted reuptake-deficient or wild-type dopaminergic neurons improve ON L-dopa dyskinesias without OFF-dyskinesias in a rat model of Parkinson's disease.
    Vinuela A; Hallett PJ; Reske-Nielsen C; Patterson M; Sotnikova TD; Caron MG; Gainetdinov RR; Isacson O
    Brain; 2008 Dec; 131(Pt 12):3361-79. PubMed ID: 18988638
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serotonergic mechanisms responsible for levodopa-induced dyskinesias in Parkinson's disease patients.
    Politis M; Wu K; Loane C; Brooks DJ; Kiferle L; Turkheimer FE; Bain P; Molloy S; Piccini P
    J Clin Invest; 2014 Mar; 124(3):1340-9. PubMed ID: 24531549
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of safinamide on the glutamatergic striatal network in experimental Parkinson's disease.
    Sciaccaluga M; Mazzocchetti P; Bastioli G; Ghiglieri V; Cardinale A; Mosci P; Caccia C; Keywood C; Melloni E; Padoani G; Vailati S; Picconi B; Calabresi P; Tozzi A
    Neuropharmacology; 2020 Jun; 170():108024. PubMed ID: 32142791
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.